Orphazyme A/S (ORPHY)

OTCMKTS: ORPHY · Delayed Price · USD
0.00
0.00 (0.00%)
May 24, 2022 4:14 AM EDT - Market closed
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out35.31M
EPS (ttm)-3.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Beta1.07
AnalystsSell
Price Target14.24
Earnings Daten/a

About ORPHY

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In...

IndustryBiotechnology
IPO DateSep 29, 2020
CEOKim Stratton
Employees180
Stock ExchangeOTCMKTS
Ticker SymbolORPHY
Full Company Profile

Financial Performance

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 9 analysts, the average rating for ORPHY stock is "Sell." The 12-month stock price forecast is 14.24, which is a change of from the latest price.

Price Target
$14.24
Analyst Consensus: Sell
Stock Forecasts

News

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPhar...

Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355

Other symbols:KMPH
1 week ago - GlobeNewsWire

Orphazyme announces update on in-court restructuring proceedings

Orphazyme A/S in restructuring Company announcement No. 23/2022Inside information  www.orphazyme.com Company Registration No. 32266355

3 weeks ago - GlobeNewsWire

Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs

Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for ...

2 months ago - Benzinga

Dear ORPH Stock Fans, Mark Your Calendars for March 31

After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appe...

2 months ago - InvestorPlace

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of N...

Orphazyme A/S Company announcement No. 13/2022Inside information www.orphazyme.com Company Registration No. 32266355

2 months ago - GlobeNewsWire

Orphazyme A/S has filed for voluntary delisting of ADSs

Orphazyme A/S Company announcement No. 12/2022 www.orphazyme.com Company Registration No. 32266355

2 months ago - GlobeNewsWire

Notice of in-court restructuring proceedings of Orphazyme A/S

Orphazyme A/S Company announcement No. 11/2022 www.orphazyme.com Company Registration No. 32266355

2 months ago - GlobeNewsWire

Why Is Orphazyme (ORPH) Stock Up Today?

The troubled biotech company's share price is up 40% despite plans to delist from the Nasdaq exchange and lay off 50% of its workers. The post Why Is Orphazyme (ORPH) Stock Up Today?

2 months ago - InvestorPlace

Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whet...

2 months ago - Benzinga

Commencement of in-court restructuring of Orphazyme A/S

Orphazyme A/S Company announcement No. 10/2022Inside information www.orphazyme.com Company Registration No. 32266355

2 months ago - GlobeNewsWire

Anders Vadsholt takes over as CEO of Orphazyme

Company announcement No. 08/2022 www.orphazyme.com Company Registration No. 32266355

2 months ago - GlobeNewsWire

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease c...

2 months ago - Business Wire

EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application

Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The applica...

2 months ago - Benzinga

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme A/S Company ann ouncement No. 07/2022Inside information www.orphazyme.com Company Registration No. 32266355

3 months ago - GlobeNewsWire

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

3 months ago - Zacks Investment Research

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease c...

3 months ago - Business Wire

Trading Penny Stocks? Top Stock Market News for February 11th, 2022

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols:CTRMMODD
3 months ago - PennyStocks

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type...

Orphazyme A/S Investor n ews No. 02/2022 www.orphazyme.com Company Registration No. 32266355

3 months ago - GlobeNewsWire

Orphazyme to present additional data on arimoclomol's mechanism of action during 2022 Annual WORLDSymposium™

Orphazyme A/S Investor News No. 01/2022 www.orphazyme.com Company Registration No. 32266355

3 months ago - GlobeNewsWire

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

Orphazyme A/S Company announcement No. 03/2022Inside information www.orphazyme.com Company Registration No. 32266355

3 months ago - GlobeNewsWire

Orphazyme Tightens FY21 Revenue Outlook

Orphazyme A/S (NASDAQ: ORPH) expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of DKK 30 million – DKK 40 million. It anticipates operating expenses of DKK 665 mil...

4 months ago - Benzinga

Orphazyme updates 2021 financial outlook

Orphazyme A/SCompany announcement No. 01/2022Inside information       Company Registration No. 32266355

4 months ago - GlobeNewsWire

Orphazyme announces changes to the Board of Directors

Orphazyme A/SCompany announcement No. 27/2021Company Registration No. 32266355

5 months ago - GlobeNewsWire

All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

Hot Penny Stocks to Buy Right Now? 3 to Watch Next Week

Which penny stocks are on your November watchlist? The post Hot Penny Stocks to Buy Right Now?

Other symbols:BESTWISH
6 months ago - PennyStocks